|By Marketwired .||
|April 7, 2014 02:00 AM EDT||
MANCHESTER, UNITED KINGDOM -- (Marketwired) -- 04/07/14 -- Epistem Holdings Plc (LSE:EHP), Manchester, UK, the biotechnology and personalized medicine company, today announced the successful installation of the Bruker Xtreme Imaging System within its contract research services division. This is the first such machine in the UK and will enable Epistem to expand both the range and throughput of its imaging services, particularly in the field of oncology. The Bruker Xtreme provides high sensitivity luminescence, fluorescence, radio-isotopic and radiographic (X-ray) imaging. Combined with Epistem's specialized pre-clinical knowledge this increases the range of assays the company can provide to its clients as well as their ability to identify new targets for cancer therapy.
"We are excited to have installed the UKs first machine. This new platform combines highly sensitive capabilities in a unified system, and provides us with a means to track tumour cells, visualise inflammation, and provide high throughput pharmacodynamic studies." said Dr. Catherine Booth, Co-Founder and Managing Director of the Contract Services Business. "Epistem's contract research service is committed to providing high quality, reliable and innovative pre-clinical models and services."
Bruker commented "The successful installation of the Xtreme system at Epistem marks our first UK site. The Xtreme is a highly sensitive imaging system with the added advantages of modularity and flexibility. It's unique design will provide major benefits to Epistem's pre-clinical drug development services."
Notes for editors
Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive®) alongside contract research services for drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine. www.epistem.co.uk
Chief Executive Officer
+44 161 606 7258
Dec. 7, 2016 12:45 PM EST Reads: 1,068
Dec. 7, 2016 12:35 PM EST Reads: 172
Dec. 7, 2016 12:30 PM EST Reads: 605
Dec. 7, 2016 12:30 PM EST Reads: 712
Dec. 7, 2016 12:30 PM EST Reads: 832
Dec. 7, 2016 12:00 PM EST Reads: 586
Dec. 7, 2016 12:00 PM EST Reads: 1,112
Dec. 7, 2016 11:47 AM EST Reads: 228
Dec. 7, 2016 11:45 AM EST Reads: 1,021
Dec. 7, 2016 11:45 AM EST Reads: 454
Dec. 7, 2016 11:30 AM EST Reads: 649
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Dec. 7, 2016 11:15 AM EST Reads: 2,284
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Dec. 7, 2016 11:01 AM EST Reads: 183
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Dec. 7, 2016 11:00 AM EST Reads: 979
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 11:00 AM EST Reads: 979